Nektar Therapeutics (NKTR)

[TREND1]

FLOAT = 87.75

[TREND1]

EPS= .07

[TREND1]

NKTR PF

[blackcat]

S&P index changes: ATI, CASY, ENR UNT, SMTC, NKTR, GCI, PGN

Also joining the S&P SmallCap 600: Nektar (NASDAQ:NKTR)

[stocktrademan]

$NKTR DD Notes ~ http://www.ddnotesmaker.com/NKTR

bullish

$NKTR recent news/filings

## source: finance.yahoo.com

Wed, 03 Dec 2014 16:57:00 GMT ~ Biotech: When and Where to Sell


read full: http://www.forbes.com/sites/tomaspray/2014/12/03/biotech-when-and-where-to-sell/?partner=yahootix
*********************************************************

Mon, 01 Dec 2014 14:18:00 GMT ~ Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A

[PR Newswire] - SAN FRANCISCO, Dec. 1, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application ...

read full: http://finance.yahoo.com/news/baxter-submits-application-us-fda-141800350.html
*********************************************************

Mon, 01 Dec 2014 10:36:59 GMT ~ Nektar Therapeutics (NKTR): Strong Industry, Solid Earnings Estimate Revisions


read full: http://finance.yahoo.com/news/nektar-therapeutics-nktr-strong-industry-103659420.html
*********************************************************

Wed, 26 Nov 2014 12:34:13 GMT ~ Will Nektar Therapeutics (NKTR) Continue to Surge Higher?


read full: http://finance.yahoo.com/news/nektar-therapeutics-nktr-continue-surge-123413446.html
*********************************************************

Mon, 24 Nov 2014 15:12:00 GMT ~ FDA Grants QIDP Designation to Bayer's Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation

[PR Newswire] - WHIPPANY, N.J., Nov. 24, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin ...

read full: http://finance.yahoo.com/news/fda-grants-qidp-designation-bayers-151200312.html
*********************************************************


$NKTR charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$NKTR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NKTR/company-info
Ticker: $NKTR
OTC Market Place: Not Available
CIK code: 0000906709
Company name: Nektar Therapeutics
Company website: http://www.nektar.com
Incorporated In: DE, USA


$NKTR share structure

## source: otcmarkets.com

Market Value: $2,049,924,840 a/o Dec 04, 2014
Shares Outstanding: 128,441,406 a/o Oct 30, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$NKTR extra dd links

Company name: Nektar Therapeutics
Company website: http://www.nektar.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NKTR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NKTR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NKTR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/news - http://finance.yahoo.com/q/h?s=NKTR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NKTR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NKTR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NKTR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nektar+Therapeutics&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nektar+Therapeutics
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nektar+Therapeutics&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nektar.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nektar.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nektar.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NKTR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000906709&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NKTR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NKTR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NKTR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NKTR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NKTR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NKTR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NKTR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NKTR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NKTR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NKTR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NKTR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NKTR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NKTR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NKTR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NKTR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NKTR



$NKTR DD Notes ~ http://www.ddnotesmaker.com/NKTR

[maytepper]

$NKTR Roth Capital Reiterates Buy On Nektar Therapeutics Following BAX-855 BLA Submission http://www.smarteranalyst.com/2014/12/02/roth-capital-reiterates-buy-on-nektar-therapeutics-following-bax-855-bla-submission/

[ClayTrader]

* * $NKTR Video Chart 9-16-14 * *

Link to Video - click here to watch the technical chart video

[maytepper]

$NKTR Nektar: Movantik Approval Unlocks Significant Economic Value for Nektar, Says William Blair http://www.smarteranalyst.com/2014/09/16/nektar-movantik-approval-unlocks-significant-economic-value-for-nektar-says-william-blair/

[Ratan09]

That is correct, guess I am still sleepy, thanks for the correction.

[$$$eeker]

$NKTR is having a PDUFA on 9/16

[Ratan09]

PDUFA for MOVANTIK on Sept 16th

[Ratan09]

Picked some up here @13.96

[maytepper]

Roth Capital Reiterates Buy On Nektar Therapeutics; Sees 46% Potential Upside http://www.smarteranalyst.com/2014/08/25/william-blair-maintains-outperform-on-el-pollo-loco-following-20-new-franchise-agreements/

[RealGenius]

600K shares in AH

[blackcat]

Sweet. I'm awfk but looking forward to the next several days as we see how she trades going forward.

[mathew633]

NKTR...trading halt lifted and trading at 13.90 with high of 15.00

[blackcat]

Thanks! I looked through the materials, but missed the meeting URL. I do like to follow along when I can. (Although I sometimes get totally lost)

[ghmm]

Its a two day panel so I imagine the vote is just tomorrow. You can watch (free) here if your interested:

https://collaboration.fda.gov/aadpac614/
(use Guest login)

other info available here:
http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ucm390304.htm

[mathew633]

No I don't

[blackcat]

Does anyone have a link so we can follow the voting when it happens?

[mathew633]

Trading halted this morning

[mathew633]

Good to see us making a nice move today into the 6/11 AdCom

[mathew633]

NKTR...news this evening, positive data release

http://ih.advfn.com/p.php?pid=nmona&article=62403071&symbol=NKTR

[mathew633]

NKTR...AdCom set for 6/11-12

http://www.biopharmcatalyst.com/2014/03/nktr-adcom-date-set-icpt-meets-phase-3-poise-endpoint-gwph-ino-updates/

[TheFinalCD]

NKTR 8-K http://archive.fast-edgar.com//20140121/AE2BGQ2CZC2ROZZK222C2ZXQSBRNZZ22Z262/

[surf1944]

8:15AM Nektar Therapeutics: Etirinotecan Pegol (NKTR-102) passes interim efficacy analysis for BEACON pivotal Phase 3 clinical study in patients with metastatic breast cancer (NKTR) 12.38 : Co announces that the Independent Data Monitoring Committee created to provide safety oversight for the Company's pivotal clinical study for etirinotecan pegol (NKTR-102) has recommended continuation of the BEACON phase 3 trial, based upon the completion of a planned interim efficacy analysis in accordance with the DMC charter. The BEACON trial is evaluating NKTR-102 versus an agent of physician's choice for the treatment of locally recurrent or metastatic breast cancer, with a primary efficacy endpoint of overall survival. NKTR-102 is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics.

The independent DMC performed the pre-defined interim efficacy analysis, which consisted of a review of ongoing efficacy and safety data, including 50% of patient events necessary to evaluate the primary endpoint of overall survival. In August 2013, the BEACON study completed enrollment of 852 patients with advanced breast cancer whose disease has progressed following treatment with anthracycline, taxane and capecitabine therapies.

[surf1944]

6:52AM Nektar Therapeutics reported that partner AstraZeneca (AZN) announced European Medicines Agency acceptance of Marketing Authorisation Application for Naloxegol (NKTR) 10.54 : Co reported that AstraZeneca (AZN) announced that the European Medicines Agency has accepted the Marketing Authorisation Application for Naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist, which has been specifically designed for the treatment of opioid-induced constipation for adult patients 18 years and older, including patients with inadequate response to laxatives. The MAA filing was based on comprehensive data from the core Phase III KODIAC programme, comprised of four clinical trials designed to investigate the safety and efficacy of naloxegol for the treatment of OIC.

Naloxegol is part of the exclusive worldwide license agreement announced on 21 Sep 2009, between AstraZeneca and Nektar Therapeutics. Under the terms of the recently amended License Agreement, AstraZeneca will pay Nektar a $25 mln milestone within five business days of acceptance of the MAA by the EMA.

[surf1944]

1:38AM Nektar Therapeutics presents target-specific biomarkers being assessed in ongoing Phase 3 BEACON study of etirinotecan pegol for the treatment of metastatic breast cancer (NKTR) 9.47 : Co announces a series of target-specific biomarkers that are being evaluated in the development of etirinotecan pegol for the treatment of breast cancer. A series of assays for target-specific pharmacodynamic biomarkers for etirinotecan pegol, including the molecular target topoisomerase I, have been established and are being measured in the Phase 3 BEACON study. The biomarkers were identified from Circulating Tumor Cell samples which were collected prior to patient treatment. Additional CTC patient samples are being collected at regular intervals during treatment and at the end of treatment.

Preliminary results from the initial pre-dose samples found CTCs in over 90% of patient samples, with a median of 200 CTCs per 7.5 mL blood draw. Patient participation in the CTC sub-set of the BEACON study is projected to be over 75%. Measurements of each biomarker expression over time will be analyzed in order to identify potential predictive biomarkers for clinical response to etirinotecan pegol.

[pammy]

does nektar manufacture medical marijuana?

[surf1944]

1:38AM Nektar Therapeutics reports positive preclinical data for NKTR-214, an investigational cancer immunotherapy targeting the il-2 receptor complex (NKTR) 10.50 : Co presents positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex. NKTR-214 is a new immunocytokine that is being developed as a potential treatment for multiple cancers. NKTR-214 targets the IL-2 receptor complex through selective receptor binding to the IL2Rb subtype. Activation of the IL2Rb subtype promotes tumor killing by the body's own immune system.

In the preclinical data presented at AACR, NKTR-214 exhibits differentiated IL-2 receptor binding which results in significantly altered immune cell populations in the tumor microenvironment compared to the clinically validated IL-2 protein therapy, aldesleukin. Specifically, NKTR-214 maintains high affinity for the IL-2 receptor subunit beta, which activates tumor-killing T cells within the tumor microenvironment. At the same time, NKTR-214 exhibits up to 100-fold reduced affinity to the IL-2 receptor subunit alpha-beta, which activates immuno-suppressive regulatory T-cells. In a well-validated animal model of melanoma, NKTR-214 demonstrated significantly improved dosing, at once every 9 days as compared to twice a day dosing with aldesleukin.

[surf1944]

8:33AM Nektar Therapeutics intiates investigator-initiated trial evaluating Etirinotecan Pegol as a third-line treatment in patients with metastatic and recurrent non-small cell lung cancer (NKTR) 8.88 : Co announces the start of a Phase 2 investigator-initiated study of etirinotecan pegol in patients with metastatic and recurrent NSCLC. The primary endpoint of the Phase 2 study is overall response rate. Secondary endpoints include progression free survival, overall survival, median duration of response and the safety profile of etirinotecan pegol in patients with NSCLC after failure of second-line therapy. The open label, single-arm trial is expected to enroll ~37 patients who will receive etirinotecan pegol once every 3 weeks as monotherapy.

[surf1944]

Bull keeps faith even as Nektar slips
By Mike Yamamoto ([e-mail]) | optionMONSTER – Fri, Jan 25, 2013 5:47 AM EST

Nektar Therapeutics has cooled after rebounding sharply this year, but one trader apparently believes that the stock will resume its run in coming months.

optionMONSTER's Heat Seeker system shows that a trader sold 3,000 May 8 calls for $1.55 and
bought the same number of August 10 calls for $1.10. The May options were below previous open interest while the August contracts were above it.

This indicates that the investor is closing the May 8 calls, which are now in the money , and is rolling the position to the higher strike in August. The trader probably made a profit on the initial calls and is using those gains to buy another three months of upside exposure.

The new long calls , which lock in the price where the stock can be bought, are now looking for NKTR to trade above $10 by mid-August but will expire worthless if the stock is below that strike price. The move follows another roll from the May 8 calls on Jan. 16 . (See our Education section)

NKTR slipped 1.72 percent to $8.57 yesterday, continuing to drift lower since hitting resistance around the $9.50 level last week. The clinical-stage biopharmaceutical company plunged from above $10 in mid-October to below $6 less than a month later but then bounced sharply.

Yesterday's call roll made up almost all of the option volume in the name, which was about 6 times its daily average in the last month. Only 26 puts changed hands in the entire session, a further reflection of the day's bullish sentiment.

[Odeen Odessit]

Breakout!

Loaded 6.50sss. Looking for 200 dma

[pj McMulligan]

Nice pincher breaking outtie! :)

[surf1944]

6:31AM Nektar Therapeutics announces top-line Phase III results from naloxegol pivotal trials in patients with opioid-induced constipation (NKTR) 8.15 : Co announced positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC). These Phase III KODIAC trials evaluated the safety and efficacy of naloxegol, an oral peripherally-acting, mu-opioid receptor antagonist for the treatment of OIC, a common side effect of prescription opioids. Under the design of both trials, statistical significance for the primary endpoint would be achieved if at least one of the two naloxegol doses had a p-value <0.025 compared with placebo. Analysis of the data indicates that in KODIAC-04 both naloxegol doses (12.5 mg and 25 mg) demonstrated statistically significant results for the primary endpoint. P-values were 0.015 and 0.001 respectively. In KODIAC-05, the 25 mg dose demonstrated a statistically significant result for the primary endpoint but the 12.5 mg dose did not. P-values were 0.202 for 12.5 mg and 0.021 for 25 mg. The analyses also showed no clinically relevant imbalances in serious adverse events (SAEs), including externally adjudicated major cardiovascular events, across the three treatment arms in KODIAC-04, -05 and -07. The most common adverse events (AEs) in the naloxegol treatment arms in both trials were abdominal pain, diarrhea and nausea.

[surf1944]

8:07AM Nektar Therapeutics announces that FDA grants fast track designation to Etirinotecan Pegol (NKTR-102) for the treatment of metastatic breast cancer (NKTR) 8.85 : Co announced that the U.S. Food and Drug Administration has designated etirinotecan pegol (NKTR-102) as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine (ATC). Etirinotecan pegol is a unique, targeted topoisomerase I inhibitor designed using Nektar's proprietary polymer conjugate technology. The drug candidate is currently being evaluated in a Phase 3 study in women with metastatic breast cancer.

[surf1944]

Nektar Therapeutics' CEO Presents at UBS Global Life Sciences Conference - Transcript

http://seekingalpha.com/article/876911-nektar-therapeutics-ceo-presents-at-ubs-global-life-sciences-conference-transcript?source=yahoo

[surf1944]

8:01AM Nektar Therapeutics announces private placement of $125 mln of senior secured notes due in 2017 (NKTR) 8.34 : Co announced the private placement of $125 million of 12.0% Senior Secured Notes Due in 2017 in an offering exempt from the registration requirements of the Securities Act of 1933. Nektar intends to use the net proceeds from the offering of the Senior Secured Notes towards the repayment of its Convertible Subordinated Notes due September 28, 2012. The sale of the Senior Secured Notes is expected to close on July 11, 2012, subject to customary closing conditions.

[surf1944]

8:03AM Nektar Therapeutics announces that FDA grants Fast Track designation to NKTR-181 for the treatment of moderate to severe chronic pain (NKTR) 6.82 : Co announced that the FDA as designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain. NKTR-181 is a novel mu-opioid agonist molecule, which is designed to have a slow rate of entry into the brain to reduce the attractiveness of the molecule as a target of abuse and to reduce its CNS-mediated side effects. Nektar requested Fast Track designation from the FDA for NKTR-181 based upon what is known about its safety and efficacy profile to-date from both preclinical and Phase 1 clinical studies, as well as NKTR-181's potential to treat chronic pain conditions with an improved safety profile over existing therapies. Given the properties and potential of NKTR-181 in the treatment of chronic pain, Nektar believes that this promising therapy could provide a unique solution to pain management with its intrinsic abuse deterrent design.

[dangerx]

Good stock to watch for the time being. I currently have 3 pharmaceutical stocks on my radar and the stocks for all 3 seem to have a similar niche within the industry. I see the downside potential of Nektar being similar to Anthera Pharmaceuticals (AN*TH) which dropped from ~$7 to $2 after missing on a late stage clinical trial. The upside potential looks similar to Vivus pharmaceuticals (VV*US), which jumped from ~$8 to ~$26 after approval on two drug candidates. Pharmaceutical R&D is almost always a gamble, but by the time investors know whether a drug candidate is going to make it to the market, it will be too late to get in a position to maximize profit (or minimize loss) GLTA!

[dangerx]

Great DD here, Surf! The two drug candidates currently in clinical trials and the 124 million dollar deal for the royalties on Cimzia and Mircera have made this long term biotech gamble a lot more appealing. Corporate updates for the BEACON phase III trial for NKTR-102 can be found on the company's website: http://www.nektar.com/product_pipeline/oncology_nktr-102.html and the NIH information on the status of the clinical trial can be found here: http://clinicaltrial.gov/ct2/show/NCT01492101?term=BEACON&rank=2

It may be a little early to buy and hold, though... the primary outcome for the BEACON trial is overall survival after 36 months, and the trial is still recruiting new patients, but from what I can tell, the current financials look good for a biotech company (increased rev on sales and licensing of their technology platform, increased assets from the sale of royalties). If any seasoned trader has an eye on this company, could you please share what you're seeing from a technical analysis view point? My background is in pharmacy, not business, but if near-dollar swings are gonna be the norm with this stock, it could be fun to play with until the results from the clinical trials are announced.

[ghmm]

I wouldn't put too high of expectations. I was very bullish on 102 in Ovarian cancer but the company talking less about it and the enrollment being stopped early (perhaps due to shortages of doxil?) make odds on an accelerated filing very, very unlikely.

On the 118 front AZ has two more studies look like drug-drug interaction studies. For whatever people may say about competition in the space by the number of trials and AZ continuing to feature it I think we stand a good chance to perhaps get a broader label and certainly have a strong marketing effort (presuming the data look good and we get approved of course).
http://www.clinicaltrials.gov/ct2/show/NCT01533870
http://www.clinicaltrials.gov/ct2/show/NCT01533155

[easymoney123]

I'm interested in NKTR-102 Phase 2 expansion study in ovarian cancer at Nektar's R&D Day on April 16, hope to hear positive news.

[surf1944]

8:55AM On The Wires (WIRES) :Nektar Therapeutics (NKTR) announced that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the co's short-acting mu-opioid analgesic candidate.

[easymoney123]

Upcoming catalysts:

http://views.thomsononeim.com/gateway/PORTALSxDOCUMENTVIEWER.aspx?DocId=59155412&mode=plain&relateditems=false

[easymoney123]

Surf, are you still holding NKTR?

[surf1944]

8:04AM Nektar Therapeutics confirmed that partner Affymax (AFFY) has announced FDA approval of OMONTYS (NKTR) 8.21 : Co reported that its partner Affymax announced that the FDA has approved OMONTYS Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. Nektar and Affymax have an exclusive agreement under which Nektar provides Affymax with its proprietary PEGylation technology for use in OMONTYS. Under the terms of the agreement, Nektar is entitled to milestones, manufacturing revenues, and royalties on the global sales of OMONTYS.

[easymoney123]

NKTR, its time to make money. GO AFFY.

[mlkrborn]

"Nektar Therapeutics announces agreement to sell Cimzia and Mircera royalties to Royalty Pharma for $124 mln (NKTR) 6.75 : Co announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA, under Nektar's agreement with UCB Pharma, and MIRCERA, under Nektar's agreement with Roche (RHHBY). In consideration for the sale, Royalty Pharma will pay Nektar an aggregate cash payment of $124.0 million. Nektar intends to use the net proceeds of the transaction towards the repayment of its $215.0 mln of convertible debt. For the twelve month period ended December 31, 2011, Nektar recognized $8.3 mln in aggregate royalties from net sales of CIMZIA and MIRCERA."

[kzivann]

http://finance.yahoo.com/news/nektar-therapeutics-announces-agreement-sell-133000525.html